AVXL Anavex Life Sciences Corp. Stock Quote

AVXL [NASD]

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	3.63%	Shs Outstand	69.49M	Perf Week	3.49%
Market Cap	913.29M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.05%	Shs Float	67.14M	Perf Month	114.45%
Income	-27.50M	PEG	-	EPS next Q	-0.14	Inst Own	20.80%	Short Float	5.97%	Perf Quarter	153.59%
Sales	-	P/S	-	EPS this Y	16.00%	Inst Trans	12.38%	Short Ratio	1.02	Perf Half Y	228.14%
Book/sh	0.72	P/B	18.14	EPS next Y	-3.70%	ROA	-72.70%	Target Price	14.60	Perf Year	219.32%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-89.60%	52W Range	2.20 - 28.70	Perf YTD	141.85%
Dividend	-	P/FCF	-	EPS past 5Y	7.10%	ROI	-	52W High	-54.49%	Beta	0.85
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	-	Gross Margin	-	52W Low	493.64%	ATR	1.64
Employees	20	Current Ratio	6.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	62.92	Volatility	8.10% 17.04%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-1.50%	Profit Margin	-	Rel Volume	0.54	Prev Close	12.36
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 11 AMC	Payout	-	Avg Volume	3.92M	Price	13.06
Recom	1.70	SMA20	14.82%	SMA50	63.36%	SMA200	140.93%	Volume	2,126,295	Change	5.66%

Dec-16-20

Reiterated

H.C. Wainwright

Buy

$14 → $17

Sep-28-20

Initiated

Ladenburg Thalmann

Buy

$12

Feb-27-20

Initiated

Cantor Fitzgerald

Overweight

Jun-18-19

Initiated

Janney

Buy

May-16-18

Resumed

Maxim Group

Buy

$5 → $7

Mar-08-18

Initiated

ROTH Capital

Buy

Feb-13-18

Reiterated

Maxim Group

Buy

$14 → $5

Sep-29-17

Resumed

Noble Financial

Buy

$15

Feb-07-17

Initiated

Noble Financial

Buy

$16

Mar-29-16

Initiated

FBR Capital

Outperform

$10

Feb-22-21 07:00AM	Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® GlobeNewswire
Feb-19-21 07:00AM	Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit GlobeNewswire
Feb-18-21 07:00AM	Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 GlobeNewswire
Feb-11-21 10:01PM	Anavex Life Sciences (AVXL) Q1 2021 Earnings Call Transcript Motley Fool -7.06%
02:30PM	Anavex Life Sciences Corp. to Host Earnings Call ACCESSWIRE
07:00AM	Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook GlobeNewswire
Feb-10-21 10:21AM	Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss Zacks -8.81%
Feb-08-21 08:22AM	What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock Barrons.com +13.80%
07:00AM	Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 GlobeNewswire
Feb-05-21 09:15AM	NASDAQ, S&P Back at Record Closing Highs Zacks -16.90%
09:10AM	Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options Zacks
Feb-04-21 01:54PM	Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High Investor's Business Daily +43.64%
Feb-03-21 06:40PM	Biotech Bonanza: COVID Launches Science at Warp Speed Zacks +37.85%
Feb-01-21 10:28AM	Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib Zacks
10:25AM	Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase Zacks
Jan-28-21 10:12AM	Global Blood's (GBT) MAA for Oxbryta Accepted in Europe Zacks +5.14%
Jan-27-21 11:13AM	Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA Zacks
Jan-11-21 07:00AM	Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinsons Disease GlobeNewswire
Jan-06-21 07:00AM	Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire +5.61%
Jan-04-21 09:30AM	Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study Zacks
Dec-31-20 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why Zacks
Dec-28-20 02:30PM	Anavex Life Sciences Corp. to Host Earnings Call ACCESSWIRE
07:00AM	Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates GlobeNewswire
Dec-22-20 07:00AM	Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 GlobeNewswire -6.93%
Dec-21-20 07:00AM	Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co. GlobeNewswire +7.27%
Dec-15-20 05:57PM	Why Anavex Life Sciences Stock Jumped Today Motley Fool +15.41%
07:00AM	Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome GlobeNewswire
Nov-30-20 07:00AM	Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders GlobeNewswire
Nov-27-20 10:00AM	Where Do Hedge Funds Stand On Anavex Life Sciences Corp. (AVXL)? Insider Monkey
Nov-25-20 07:00AM	Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire +5.05%
Nov-06-20 10:45AM	Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinsons Disease Dementia Presented at CTAD 2020 Conference GlobeNewswire -35.22%
Oct-16-20 08:54AM	Anavex (AVXL) in Focus: Stock Moves 9.5% Higher Zacks
Oct-15-20 03:13PM	Here's Why Anavex Life Sciences Jumped Higher Today Motley Fool +9.45%
07:00AM	Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinsons Disease Dementia GlobeNewswire
Sep-10-20 07:00AM	Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire
Sep-08-20 07:00AM	Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences GlobeNewswire
Sep-02-20 07:01AM	We're Not Very Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Rate Simply Wall St.
Aug-19-20 07:00AM	Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinsons Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinsons Disease GlobeNewswire
Aug-06-20 07:00AM	Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates GlobeNewswire -6.81%
Aug-05-20 04:05PM	Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimers Disease Patients GlobeNewswire -5.21%
Aug-04-20 07:00AM	Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 GlobeNewswire +8.60%
Jul-06-20 07:00AM	Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire -6.06%
Jul-01-20 07:00AM	Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome GlobeNewswire
Jun-26-20 12:00PM	Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy Zacks
Jun-18-20 11:30AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? Zacks +20.70%
Jun-16-20 07:00AM	Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire
Jun-15-20 12:00PM	Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the Upgrade Zacks +8.22%
Jun-14-20 09:07PM	Should You Buy Anavex Life Sciences Corp. (AVXL)? Insider Monkey
Jun-12-20 09:45AM	3 Strong Buy Penny Stocks With Massive Upside Ahead TipRanks
Jun-11-20 06:15PM	Edited Transcript of AVXL earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents -10.96%
Jun-04-20 07:00AM	Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimers Disease GlobeNewswire
Jun-02-20 11:30AM	Has Anavex Life Sciences (AVXL) Outpaced Other Medical Stocks This Year? Zacks
Jun-01-20 07:59AM	Anavex's Shares March Higher, Can It Continue? Zacks
May-21-20 07:00AM	Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire
May-14-20 10:07AM	Why You Shouldn't Bet Against Anavex Life Sciences (AVXL) Stock Zacks -7.67%
May-13-20 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why Zacks
May-07-20 07:00AM	Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates GlobeNewswire
May-05-20 07:00AM	Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020 GlobeNewswire
Apr-23-20 07:00AM	Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimers Disease GlobeNewswire
Apr-14-20 11:48AM	Will Anavex Life Sciences Continue to Surge Higher? Zacks +7.52%
Apr-03-20 05:45PM	Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should Know Zacks
Mar-31-20 07:00AM	Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 GlobeNewswire
Mar-23-20 08:00AM	Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders GlobeNewswire +15.64%
Feb-24-20 07:00AM	Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire -7.27%
Feb-17-20 12:00PM	All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Strong Buy Zacks
11:30AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? Zacks
Feb-14-20 09:18AM	Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-13-20 12:48PM	4 Momentum Stocks To Watch Benzinga +7.00%
Feb-11-20 09:22AM	Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA Zacks +6.25%
Feb-10-20 10:56PM	Edited Transcript of AVXL earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-06-20 02:30PM	Anavex Life Sciences Corp. to Host Earnings Call ACCESSWIRE +9.79%
07:00AM	Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire
Feb-04-20 07:00AM	Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire +9.15%
Feb-03-20 07:00AM	Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome GlobeNewswire +14.69%
Jan-31-20 11:30AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? Zacks
Jan-30-20 07:00AM	Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire
Jan-27-20 07:00AM	Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinsons Disease Dementia (PDD) Clinical Trial GlobeNewswire
Jan-23-20 08:42AM	Implied Volatility Surging for Anavex (AVXL) Stock Options Zacks
Jan-17-20 08:16AM	Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status Zacks
Jan-15-20 04:34PM	Alexion to Start Pivotal Study on Ultomiris for ALS in Q1 Zacks
Jan-14-20 12:00PM	Anavex Life Sciences (AVXL) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
Jan-08-20 08:53AM	Amarin Posts '19 Preliminary Results, Gives 2020 Expense View Zacks
08:12AM	The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results Benzinga
07:00AM	Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis GlobeNewswire
05:00AM	Top Picks 2020- Anavex AVXL MoneyShow
Dec-27-19 06:34AM	Will Anavex Life Continue to Surge Higher? Zacks -8.96%
Dec-23-19 07:57PM	Hedge Funds Arent Crazy About Anavex Life Sciences Corp. (AVXL) Anymore Insider Monkey
Dec-18-19 01:37AM	Edited Transcript of AVXL earnings conference call or presentation 16-Dec-19 9:30pm GMT Thomson Reuters StreetEvents
Dec-16-19 07:00AM	Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire
Dec-10-19 07:00AM	Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire
Dec-04-19 10:13AM	Anavex shares rise in advance of Alzheimer's meeting MarketWatch +28.39%
07:00AM	Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference GlobeNewswire
Nov-14-19 07:00AM	Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome GlobeNewswire
Nov-06-19 07:00AM	Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire -5.90%
Oct-23-19 09:00AM	All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy Zacks
Oct-11-19 02:04AM	Edited Transcript of AVXL earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-09-19 07:00AM	Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimers Disease GlobeNewswire
Oct-02-19 07:00AM	Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimers Disease GlobeNewswire
Sep-27-19 07:56AM	The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave Benzinga
03:00AM	Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study GlobeNewswire

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donhauser Peter D.O.	Director	Feb 19	Buy	12.67	1,165	14,760	1,165	Feb 23 01:22 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience